COMMUNIQUÉS West-GlobeNewswire

PridCor Therapeutics Reports Positive Long COVID Case Series with Combination Antiviral Regimen
04/09/2025
-New Preprint: PridCor Therapeutics LLC has released a pre-print detailing a case series of 15 patients with Long COVID (LC) who were given a continuous regimen of 120-days of valacyclovir and celecoxib with a pulsed 15 [...]
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
04/09/2025
Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5 th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation [...]
Bay Area Lyme Foundation Launches Bay Area Lyme Ventures as First Impact Investment Fund to Support Entrepreneurs and Companies Advancing Lyme Disease Solutions
04/09/2025
New venture philanthropy fund announces initial investments and will help guide game-changing Lyme diagnostics and therapeutics to commercialization PORTOLA VALLEY, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bay Area [...]
Legend Senior Living Welcomes Annalisa Hahn as Senior Vice President of Sales and Marketing
04/09/2025
WICHITA, Kan., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Legend Senior Living, a nationally recognized senior living provider with more than 70 residences across seven states, is pleased to announce the appointment of Annalisa [...]
OSE Immunotherapeutics : une stratégie claire, une gouvernance équilibrée, un cap affirmé vers la création de valeur
04/09/2025
OSE Immunotherapeutics : une stratégie claire, une gouvernance équilibrée, un cap affirmé vers la création de valeur NANTES, France – 4 septembre 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: [...]
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
04/09/2025
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation NANTES, France – September 4, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) [...]
OSE Immunotherapeutics : une stratégie claire, une gouvernance équilibrée, un cap affirmé vers la création de valeur
04/09/2025
OSE Immunotherapeutics : une stratégie claire, une gouvernance équilibrée, un cap affirmé vers la création de valeur NANTES, France – 4 septembre 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: [...]
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
04/09/2025
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation NANTES, France – September 4, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) [...]
Reverse Stock Split Strengthens HealthLynked’s Market Position as Company Scales AI-Driven Healthcare Platform
04/09/2025
NAPLES, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ) -- Dear Shareholders, I'm writing to share an important update in the continued evolution of HealthLynked Corp. that reflects [...]
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
04/09/2025
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with [...]
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
04/09/2025
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with [...]
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
04/09/2025
MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37 , the leader in expanding patient access to clinical trials, and Catalent ® , a global leader in enabling pharma, biotech, and consumer health partners to [...]
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
04/09/2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for [...]
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
04/09/2025
RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and [...]
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
04/09/2025
Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current [...]
IO Biotech Announces Participation in Upcoming Investor Conferences
04/09/2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that [...]
STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements
04/09/2025
Consulting program optimizes partner clinic businesses with implementation of best practices initiatives, including marketing, reimbursement, and patient retention HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA [...]
Sofwave Receives FDA, Pre-market Clearance for Pure Impact VIPTM Standalone EMS Device For Comprehensive Multi-Body Area Muscle Strengthening and Firming
04/09/2025
The Pure Impact VIP™ standalone device represents a major extension of the Pure Impact™ product line and introduces an all-in-one independent unit Standalone device is launched with an enhanced Pure Impact™ feature set [...]
Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
04/09/2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for its investigational compound BMB‑201, in a validated isosorbide dinitrate ( [...]

Pages